CD5-positive diffuse large B-cell lymphoma
Conditions
Interventions
Intervention group:Patients received induction therapy with the DA-EPOCH-R regimen (riximab 375 mg/m^2, d0
Etoposide 50mg/m^2/d
vinpodisin 0.8mg/m^2/d
Epirubicin 15mg/m^2/d, continuous intravenous infusion for 96h
cyclophosphamide 750mg/m^2, d5
Prednisone 60mg/m^2/d, d1-5
1 course of treatment every 3 weeks, and the dose adjustment refers to previous studies). Patients with PR or above in the mid-term evaluation of 4 courses of treatment entered the preparation stage f
Foot leaf acetoside 200mg/m^2, d6-3
cytarabine 20mg/m^2, d6-3
Inphalon 70mg/m^2, d3~2).
Sponsors
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Diagnosed by histopathology as CD5 positive diffuse large B-cell lymphoma; 2.Previously untreated; 3.ECOG score <= 2 points; 4.No serious complications, such as liver failure, kidney failure, or heart failure; 5.Voluntarily sign a written informed consent form before experimental screening; 6.18 <= Age <= 65 years old, gender not limited.
Exclusion criteria
Exclusion criteria: 1.Lymphoma involving the central nervous system; 2.Active infectious diseases such as HIV, tuberculosis; 3.Patients with severe organ dysfunction; 4.History of other active tumors; 5.Researchers believe that there are other situations that are not suitable for participating in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2y-OS; | — |
Countries
China
Contacts
Public ContactWenjuan Yu
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed